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ABSTRACT: In longitudinal PET studies, animals are repeatedly
anesthetized which may affect the repeatability of PET measure-
ments. The aim of this study was to assess the effect of anesthesia
on the P-gp function as well as the reproducibility of [18F]MC225
PET scans. Thus, dynamic PET scans with blood sampling were
conducted in 13 Wistar rats. Seven animals were exposed to
isoflurane anesthesia 1 week before the PET scan (“Anesthesia-
exposed” PET). A second group of six animals was used to evaluate
the reproducibility of measurements of P-gp function at the
blood−brain barrier (BBB) with [18F]MC225. In this group, two
PET scans were made with a 1 week interval (“Test” and “Retest”
PET). Pharmacokinetic parameters were calculated using com-
partmental models and metabolite-corrected plasma as an input
function. “Anesthesia-exposed” animals showed a 28% decrease in whole-brain volume of distribution (VT) (p < 0.001) compared to
“Test”, where the animals were not previously anesthetized. The VT at “Retest” also decreased (19%) compared to “Test” (p <
0.001). The k2 values in whole-brain were significantly increased by 18% in “Anesthesia-exposed” (p = 0.005) and by 15% in “Retest”
(p = 0.008) compared to “Test”. However, no significant differences were found in the influx rate constant K1, which is considered as
the best parameter to measure the P-gp function. Moreover, Western Blot analysis did not find significant differences in the P-gp
expression of animals not pre-exposed to anesthesia (“Test”) or pre-exposed animals (“Retest”). To conclude, anesthesia may affect
the brain distribution of [18F]MC225 but it does not affect the P-gp expression or function.
KEYWORDS: Anesthesia, blood-brain barrier, isoflurane, P-glycoprotein, positron emission tomography, preclinical studies,
test−retest reproducibility
1. INTRODUCTION
Delivery of many drugs to the central nervous system (CNS) is
reduced by the action of efflux transporters in the blood−brain
barrier (BBB), such as the breast cancer resistance protein
(BCRP), and particularly P-glycoprotein (P-gp), i.e., ABCB1.1
This transporter is known to limit the brain entry of
antipsychotics, antidepressants, antiepileptic drugs, and chemo-
therapeutic agents.2 Several structurally diverse compounds act
as substrates or modulators of P-gp. The transporter is,
therefore, involved in drug−drug interactions (DDI) at the
BBB with corresponding alterations of drug concentration,
decreases in therapeutic efficacy and increases of toxicity.3,4
For this reason, the U.S. Food and Drug Administration
(FDA) and European Medicines Agency (EMA) have
developed specific guidelines for the screening of new drugs
in order to determine their potential interactions with P-gp.5,6
In vitro screening is based on simplified models of the living
system, positron emission tomography (PET) imaging of the
mammalian brain may provide important information con-
cerning P-gp mediated drug transport and the mechanism
underlying DDIs. Several PET tracers are available for this
purpose, such as (R)-[11C]Verapamil and [11C]N-desmethyl-
loperamide.7,8 Recently, [18F]MC225 (5-(1-(2-[18F]-
fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-
2-yl)-propyl]-5,6,7,8-tetrahydronaphthalene) was developed
and validated for quantitative imaging of P-gp.9,10 This tracer
is classified as a weak substrate of P-gp, resulting in higher
brain uptake of radioactivity at baseline compared to other
imaging agents.10 Inhibitors of P-gp were shown to increase
the cerebral uptake of [18F]MC225.10
Since PET imaging is minimally invasive, this technique
seems well-suited for longitudinal studies, e.g. the scanning of a
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subject at baseline and after various interventions. However,
PET imaging of small animals involves the use of anesthesia in
order to immobilize the subject during the scan. Since it is
well-known that anesthesia may affect the distribution of
tracers in the CNS,3,11,12 it is important to examine the impact
of anesthesia on the brain uptake of P-gp tracers. Moreover,
the reproducibility of [18F]MC225 PET scans should be
assessed before longitudinal studies with this tracer can be
performed.
The present study aimed to assess the influence of previous
exposure to isoflurane anesthesia on P-gp function at the BBB
and the reproducibility of [18F]MC225 PET scans in rats.
Pharmacokinetic parameters, such as the volume of distribu-
tion (VT) and the rate constants (K1 and k2) of [
18F]MC225,
were calculated using compartmental models and metabolite-
corrected plasma radioactivity as input function. Western Blot
(WB) analysis was performed to assess the expression of P-gp
and BCRP transporters at the BBB.
2. RESULTS AND DISCUSSION
PET imaging can provide insight into the physiology and
pathophysiology of living brains.13 Moreover, it is a non-
invasive technique that allows the monitoring of animals in
longitudinal studies at several time points, before and after the
onset of disease or treatment. Thus, each animal can serve as
its own control, which reduces intersubject variability.14
However, many factors may interfere with molecular
mechanisms inside the brain and may have a negative impact
on PET measurements. These include gender and strain
differences of physiology and metabolism, the age of the
animals, the composition of the diet or the duration of the
fasting, the circadian rhythm and, the dose and kind of
Figure 1. [18F]MC225 concentration over the time course of the different PET scans: (A) metabolite-corrected time−activity curves in plasma and
(B) percentage of parent fraction as a function of time. Data are plotted as EMM ± SE.
Figure 2. Whole-brain TACs of [18F]MC225 at the three different scans.
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anesthetic.11 Therefore, the reproducibility of PET scans with a
novel tracer should be evaluated before longitudinal studies are
performed. Since anesthesia is commonly used to immobilize
animals during acquisition of PET data, animals are repeatedly
anesthetized in each longitudinal study design. Thus, it is
necessary to examine the effect of anesthesia on the imaging
target (in this case, cerebral P-gp function). To this aim,
dynamic PET scans with [18F]MC225 and blood sampling
were made in 13 healthy male Wistar rats. In order to test the
effect of the anesthesia on the P-gp function, seven animals
were exposed to isoflurane anesthesia 1 week before the PET
scan (“Anesthesia-exposed” PET). A second group of six
animals was used to evaluate the reproducibility of measure-
ments of P-gp function at the BBB with [18F]MC225. In this
group, two PET scans were made with a 1 week interval
(“Test” and “Retest” PET).
2.1. Results. 2.1.1. Tracer Production. The tracer was
obtained in an average synthesis time of 92 ± 7 min (mean ±
SD) with a radiochemical yield of 4.9 ± 0.9% (decay-
corrected). The radiochemical purity of [18F]MC225 was
higher than 99%, and the molar activity was higher than 29
TBq/mmol.
2.1.2. Plasma Kinetics and Metabolism of [18F]MC225.
Since the tracer was injected during a period of 1 min using a
Harvard infusion pump, the concentration of [18F]MC225
peaked at 62 s after the start of tracer injection in metabolite-
corrected plasma time−activity curves (TACs).
Statistical analysis revealed that the plasma concentration of
[18F]MC225 (corrected for metabolites) was significantly
higher in “Anesthesia-exposed” and “Retest” scans compared
to “Test”. Figure 1A indicates a sharper rise of [18F]MC225 in
“Anesthesia-exposed” and “Retest” scans compared to “Test”.
The parent fraction in plasma was also higher in “Anesthesia-
exposed” and “Retest” scans than in “Test”, as can be observed
in Figure 1B. Table 1 in the Supporting Information shows the
estimated marginal means (EMM) and standard errors (SE)
calculated by generalized estimated equation (GEE) analysis,
and the statistical significance of differences between scans.
However, we did not observe any statistically significant
differences in the biological half-life (T1/2) of the tracer in the
three scans (Anesthesia-exposed, Test, and Retest).
2.1.3. Brain Kinetics of [18F]MC225. 2.1.3.1. The SUV-TAC
of the Whole Brain.Whole-brain TACs are shown in Figure 2.
Although standardized uptake values (SUVs) seem higher in
the “Retest” group than in the other two groups, the statistical
analysis did not indicate any significant differences between
“Anesthesia-exposed” and “Test”, “Retest” and “Test”, or
“Anesthesia-exposed” and “Retest”.
2.1.3.2. Pharmacokinetic Modeling. Using all data of a 60
min scan, the two-tissue compartment model (2TCM) showed
lower Akaike values than the one-tissue compartment model
(1TCM) for all brain regions. Based on the AIC, the 2TCM
should be the model of choice for data analysis; however, the
standard errors (SE%) of the estimated rate constants K1 and
k2 were lower in the 1TCM than in the 2TCM. The large SE%
of K1 and k2 in the 2TCM results in extremely high K1 and k2
values in all groups (more details in supplemental Table 2).
Due to the insufficient stability of a 2TCM fit, the 1TCM was
selected as the preferred kinetic model for [18F]MC225.
Statistical analysis of the data of 1TCM fits did not find
significant differences in the K1 values between the scans.
However, the analysis found significant differences in the
Figure 3. Parametric images of representatives PET scans (Anesthesia-exposed, Test, and Retest) showing voxel-wise values for K1 of [
18F]MC225
calculated by 1TCM.
Figure 4. Parametric images of representative PET scans (Anesthesia-exposed, Test, and Retest) showing voxel-wise values for VT of [
18F]MC225
calculated by 1TCM.
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whole-brain volume of distribution (VT) between the
“Anesthesia-exposed” and “Test” scans (6.4 ± 0.4 vs 8.8 ±
0.3; p < 0.001) and also between “Retest” and “Test” (7.1 ±
0.4 vs 8.8 ± 0.3; p < 0.001) (Figure 3). Moreover, the analysis
showed that the efflux constant k2 was significantly higher in
the “Anesthesia-exposed” scans than in “Test” (0.035 ± 0.002
vs 0.030 ± 0.001; p = 0.005), and in “Retest” scans than in
“Test” (0.034 ± 0.001 vs 0.030 ± 0.001; p = 0.008). No
significant differences in the VT, k2, or K1 between the
“Anesthesia-exposed” scan and “Retest” were found.
A rise of k2 may have caused a decrease of VT in the
“Anesthesia-exposed” and “Retest” scans (see Figures 3 and 4).
Similar significant group differences in VT and k2 and a
similar absence of significant differences in K1 were observed in
the studied brain regions. Figure 5 shows the EMM ± SE of
K1, VT, and k2 in the regions analyzed.
Figure 5. Regional K1 (A), VT (B), and k2 (C) values of [
18F]MC225 at different scans. Data expressed as EMM ± SE.
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Several studies suggest that the best method to evaluate the
P-gp function is to use the first part of the PET scan after the
tracer injection.7,15 At early time points, the metabolism of the
tracer is still limited and therefore radiometabolites may not
interfere with the P-gp measurement. For this reason, the
kinetic analysis was also performed using a 30 min scan
duration. Similar results to the 60 min scan analysis were
obtained (see Table 1).
2.1.4. Test−Retest Analysis. The “Test” and “Retest” scans
did not differ significantly regarding the injected dose (31 ±
5.7 MBq; p = 0.356), the molar activity (58 ± 21.7 TBq; p =
0.868) or the radiochemical purity (99.5 ± 0.4%; p = 0.350).
Animals in “Retest” scans were 1 week older than during the
“Test”, however, no significant differences in the body weight
of animals between “Test” and “Retest” scans were found.
(weight in “Test” scans = 345 ± 29 vs weight in “Retest” = 366
± 31, p = 0.520).
The K1 values were not significantly different between “Test”
and “Retest” scans in any of the brain regions with the
exception of the medial geniculate region and septum (Table
2). Regarding the reproducibility evaluation, the relative
difference (Rel. Diff. %) in K1 between “Test” and “Retest”
scans varied from −4 to −11% and the absolute variability or
Test−Retest variability (TRV%) was lower than 12% in all the
regions. The coefficient of variance (CV%) in “Test” scans
showed an average for all the brain regions of 13 ± 2% and in
“Retest” scans of 20 ± 3%. Even though the average of the
intraclass correlation coefficient (ICC) value for all the regions
indicated a fair agreement between “Test” and “Retest” scans,
most of the regions showed ICC values between 0.5 and 0.6,
including the whole brain region, which indicated a moderate
agreement.
In the case of the VT values, the t test analysis found
significant differences in all the brain regions between “Test”
and “Retest” scans except for the septum (Table 3). The Rel.
Diff. % values in VT were larger than the ones from K1, ranging
between 16% and 24%, and TRV% was above 19% in all the
brain regions. The between-subject repeatability expressed as
Table 1. EMM ± SE VT, K1, and k2 of the Selected Brain Region Using 30 min Scan Duration and 1TCM




















amygdala 0.22 ± 0.01 0.047 ± 0 4.73 ± 0.24 0.25 ± 0.01 0.041 ± 0 6.13 ± 0.4 0.24 ± 0.02 0.045 ± 0 5.22 ± 0.24
basal ganglia 0.21 ± 0.02 0.05 ± 0 4.19 ± 0.22 0.24 ± 0.01 0.045 ± 0 5.55 ± 0.42 0.23 ± 0.02 0.053 ± 0 4.35 ± 0.22
brainstem 0.33 ± 0.02 0.057 ± 0 5.87 ± 0.32 0.38 ± 0.02 0.05 ± 0 7.69 ± 0.39 0.36 ± 0.02 0.056 ± 0 6.49 ± 0.3
cerebellum 0.3 ± 0.02 0.052 ± 0 5.74 ± 0.36 0.34 ± 0.01 0.047 ± 0 7.29 ± 0.32 0.32 ± 0.02 0.051 ± 0 6.33 ± 0.31
corpus callosum 0.2 ± 0.01 0.04 ± 0 5.06 ± 0.36 0.23 ± 0.01 0.035 ± 0 6.5 ± 0.33 0.22 ± 0.02 0.038 ± 0 5.66 ± 0.33
cortex 0.2 ± 0.01 0.034 ± 0 5.98 ± 0.4 0.23 ± 0.01 0.029 ± 0 7.9 ± 0.42 0.22 ± 0.02 0.033 ± 0 6.8 ± 0.37
hippocampus 0.21 ± 0.01 0.046 ± 0 4.53 ± 0.29 0.25 ± 0.01 0.041 ± 0 5.96 ± 0.31 0.23 ± 0.02 0.044 ± 0 5.19 ± 0.29
hypothalamus 0.26 ± 0.02 0.048 ± 0 5.44 ± 0.29 0.3 ± 0.02 0.042 ± 0 7.15 ± 0.46 0.28 ± 0.02 0.048 ± 0 5.88 ± 0.26
medial geniculate 0.22 ± 0.02 0.054 ± 0 4.26 ± 0.37 0.26 ± 0.01 0.045 ± 0 5.92 ± 0.4 0.26 ± 0.02 0.053 ± 0 4.82 ± 0.23
mesencephalic
region
0.28 ± 0.01 0.055 ± 0 5.2 ± 0.28 0.34 ± 0.02 0.051 ± 0 6.65 ± 0.39 0.31 ± 0.02 0.054 ± 0 5.88 ± 0.35
midbrain 0.28 ± 0.02 0.055 ± 0 5.15 ± 0.3 0.33 ± 0.02 0.049 ± 0 6.77 ± 0.3 0.31 ± 0.02 0.053 ± 0 5.9 ± 0.35
septum 0.22 ± 0.02 0.052 ± 0 4.23 ± 0.24 0.25 ± 0.01 0.045 ± 0 5.57 ± 0.43 0.23 ± 0.02 0.048 ± 0 4.92 ± 0.47
striatum 0.2 ± 0.02 0.047 ± 0 4.35 ± 0.27 0.23 ± 0.01 0.038 ± 0 5.91 ± 0.39 0.22 ± 0.02 0.045 ± 0 4.77 ± 0.26
superior colliculus 0.28 ± 0.02 0.061 ± 0 4.69 ± 0.26 0.32 ± 0.02 0.054 ± 0 6.06 ± 0.41 0.31 ± 0.02 0.06 ± 0 5.21 ± 0.35
thalamus 0.24 ± 0.02 0.058 ± 0 4.17 ± 0.22 0.28 ± 0.01 0.052 ± 0 5.37 ± 0.34 0.26 ± 0.02 0.057 ± 0 4.64 ± 0.29
whole brain 0.23 ± 0.02 0.044 ± 0 5.3 ± 0.31 0.26 ± 0.01 0.038 ± 0 6.89 ± 0.36 0.25 ± 0.02 0.043 ± 0 5.93 ± 0.31
Table 2. Reliability of K1 Values between “Test” and “Retest” Scans in All the Brain Regions
regions K1 Test ± SD K1 Retest ± SD Rel. Diff. K1 (%) TRV K1 (%) CV (%) K1 test CV (%) K1 Retest ICC K1
amygdala 0.24 ± 0.04 0.21 ± 0.04 −7.75 8.07 15.61 20.88 0.287
cerebellum 0.34 ± 0.03 0.3 ± 0.04 −7.86 8.18 8.65 17.44 0.15
corpus callosum 0.23 ± 0.04 0.19 ± 0.03 −7.91 8.24 15.83 24.14 0.521
medial geniculate 0.26 ± 0.04a 0.23 ± 0.03a −6.52 6.74 13.42 19.60 0.741
mesencephalic region 0.34 ± 0.03 0.29 ± 0.02 −9.95 10.47 9.48 14.89 −0.04
septum 0.25 ± 0.03a 0.2 ± 0.03a −11.07 11.72 12.72 26.20 0.537
superior colliculus 0.32 ± 0.04 0.28 ± 0.04 −5.90 6.08 12.26 18.83 0.493
striatum 0.22 ± 0.04 0.19 ± 0.03 −7.89 8.22 16.70 23.79 0.616
cortex 0.22 ± 0.03 0.2 ± 0.04 −4.01 4.09 13.44 23.11 0.692
hippocampus 0.24 ± 0.03 0.21 ± 0.04 −8.86 9.28 14.34 22.80 0.555
hypothalamus 0.3 ± 0.04 0.26 ± 0.05 −8.94 9.35 13.96 19.04 0.688
mid brain 0.33 ± 0.05 0.28 ± 0.03 −8.67 9.06 14.66 16.59 0.128
brainstem 0.38 ± 0.04 0.34 ± 0.04 −7.98 8.31 10.01 14.78 −0.021
thalamus 0.27 ± 0.04 0.23 ± 0.03 −7.53 7.82 15.02 20.94 0.428
basal ganglia 0.24 ± 0.04 0.2 ± 0.03 −9.18 9.62 15.40 21.83 0.37
whole brain 0.26 ± 0.03 0.23 ± 0.04 −6.65 6.88 12.38 20.42 0.522
mean ± SD −7.92 ± 1.66 8.26 ± 1.79 13.37 ± 2.36 20.33 ± 3.32 0.42 ± 0.25
aSignificant differences between “Test” and “Retest” scan (p < 0.05).
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CV% showed an average for all the regions of 10 ± 4% in
“Test” scans and 16 ± 2% in “Retest” scans. Most of the ICC
values for the VT varied from 0.2 to 0.3 which indicated slight
agreement between “Test” and “Retest” scans.
2.1.5. Blood Flow Analysis. The statistical analysis did not
reveal any significant difference in whole-brain SUV values of
the first frames among the three study scans (SUV
“Anesthesia-exposed” = 0.85 ± 0.049 vs SUV “Test” = 0.84
± 0.052; p = 0.876 and SUV “Retest” = 0.91 ± 0.025 vs SUV
“Test” = 0.84 ± 0.052; p = 0.276). This result indicates that
anesthesia does not cause long-term alterations of cerebral
blood flow (CBF).
2.1.6. Western Blot. Wistar rats with similar weights to the
ones used during the PET scans were used for the WB analysis.
These animals underwent the same procedures as the animals
used in the PET studies: Group “Test” was once previously
anesthetized, Group “Retest” was twice previously anesthe-
tized, and the group control was not subjected to anesthesia
before the euthanasia. WB analysis showed no significant
differences in P-gp and BCRP expression between the control
group and any of the anesthetized groups (“Test” and “Retest”
groups) (see Figures 6 and 7).
2.2. Discussion. The plasma concentration of [18F]MC225
(corrected for metabolites) was significantly higher in the scans
where the animals were pre-exposed to anesthesia, “Anesthesia-
exposed” (+25%) and “Retest” (+19%). Moreover, the parent
fraction of plasma radioactivity was slightly but significantly
increased by 6% in “Anesthesia-exposed” animals and by 5% in
“Retest”, both compared to “Test”. However, we did not
observe significant differences in T1/2 among the scans. These
results suggest that previous exposure to anesthesia may affect
Table 3. Reliability of the VT Values between “Test” and “Retest” Scans in All the Brain Regions
regions VT Test ± SD VT Retest ± SD Rel. Diff. VT (%) TRV VT (%) CV (%) VT test CV (%) VT Retest ICC VT
amygdala 8.22 ± 1.24a 6.28 ± 0.91a −21.61 24.23 15.07 14.07 0.512
cerebellum 9.17 ± 0.33a 7.42 ± 1.08a −18.29 20.13 3.62 14.42 0.236
corpus callosum 8.31 ± 0.58a 6.49 ± 1.03a −19.63 21.76 6.97 15.49 0.225
medial geniculate 7.01 ± 0.7a 5.49 ± 0.96a −20.52 22.86 9.95 17.28 0.372
mesencephalic region 8.01 ± 0.82a 6.62 ± 1.11a −16.13 17.55 10.19 16.58 0.533
septum 7.04 ± 0.93 5.59 ± 1.29 −17.18 18.79 13.25 22.08 0.317
superior colliculus 7.44 ± 0.9a 6.05 ± 1.12a −17.55 19.24 12.12 18.23 0.575
striatum 7.35 ± 0.87a 5.55 ± 0.82a −22.75 25.67 11.86 14.45 0.354
cortex 10.31 ± 0.62a 8.12 ± 1.25a −20.09 22.34 5.97 15.23 0.259
hippocampus 7.7 ± 0.62a 6.14 ± 0.93a −18.16 19.97 8.07 14.76 0.338
hypothalamus 8.99 ± 1.45a 6.92 ± 0.95a −22.00 24.73 16.13 13.56 0.494
mid brain 8.19 ± 0.39a 6.77 ± 1.06a −17.14 18.75 4.76 15.65 0.313
brainstem 9.27 ± 1.04a 7.45 ± 1.09a −19.50 21.61 11.26 14.61 0.57
thalamus 6.66 ± 0.79a 5.22 ± 0.94a −19.90 22.10 11.86 17.56 0.506
basal ganglia 6.85 ± 1.11a 5.06 ± 0.69a −24.23 27.57 16.15 13.33 0.434
whole brain 8.81 ± 0.67a 7 ± 1.07a −19.18 21.22 7.58 15.01 0.373
mean ± SD −19.62 ± 2.23 21.78 ± 2.75 10.3 ± 3.89 15.77 ± 2.2 0.4 ± 0.12
aSignificant differences between Test and Retest scan (p < 0.05)
Figure 6. Western Blot bands corresponding to P-gp, BCRP, and β-actin (160, 72, and 42 kDa predicted molecular weight, respectively).
Figure 7. BCRP and P-gp expression in control animals, group “Test”
(one time anesthetized) and group “Retest”(twice anesthetized).
Expression was related to β-actin and then normalized to protein
expression found in control animals. Data are shown as mean ± SE (n
per group = 4 with duplicates).
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the tracer concentration in plasma but not its rate of
elimination.
Previous PET studies in rodents have identified 1TCM as
the preferred model to analyze [18F]MC225 kinetics.10 In our
own study, 1TCM was also chosen as the best model to fit the
data. The model fit indicates a significant decrease in the VT of
[18F]MC225 in whole-brain and all analyzed brain regions of
animals pre-exposed to isoflurane-anesthesia (“Anesthesia-
exposed” and “Retest”). We also observed a significant increase
in k2 values of the tracer in whole-brain and in most brain
regions analyzed. Whole-brain VT was 28% lower in
“Anesthesia-exposed” and 19% lower in “Retest” than in
“Test” scans. Meanwhile, whole-brain k2 was 18% and 15%
higher in “Anesthesia-exposed” and “Retest” scans compared to
“Test”. On the other hand, tracer levels in the blood were
higher in animals pre-exposed to anesthesia (“Anesthesia-
exposed” and “Retest” scans) than in “Test”. However, the
whole-brain SUV-TACs in the three scans were not
significantly different. These changes may be related, i.e. the
decrease in VT due to previous exposure to anesthesia may be
caused by the increase in k2, resulting in reduced brain uptake
and increased concentration of the radiotracer in plasma.
However, the 1TCM fit did not indicate significant changes in
the K1, which is considered by many authors as the best
parameter to measure the P-gp function at the BBB.7,8,10,15−17
Previous validation of [18F]MC225 as a tracer for measuring
P-gp function at the BBB of rats found a significant increase in
the K1 and VT after the administration of the P-gp inhibitor
tariquidar. This analysis also indicated that K1 values were
stable during the whole PET scan, whereas the VT values
became stable only after 30 min scan duration. Furthermore,
after P-gp inhibition, the observed changes in K1 were larger
than the changes in VT. Therefore, this study concluded that
K1 is the best parameter to measure the P-gp function,
although VT may also be used when sufficient scan data (>30
min) are available.10
In contrast to these findings, the pharmacokinetic evaluation
of [11C]metoclopramide, another tracer considered as a weak
P-gp substrate, indicated a significant decrease in the efflux
constant k2 values after the administration of tariquidar which
caused a significant increase of the brain VT in rats and
nonhuman primates.18,19 The authors of these studies suggest
the use of k2 as the best parameter to measure the P-gp
function. Nevertheless, it has been discussed that VT and k2
parameters can be affected by nonspecific trapping of the tracer
and can also be affected by the fraction of radiometabolites
inside the brain.7,15
One strategy to avoid the interference of radiometabolites in
the kinetic evaluation is to use short scan duration, such as 30
min scans. For instance, Muzi et al. suggested the use of K1
calculated with 1TCM and a 30 min scan to evaluate the P-gp
function at the human BBB using [11C]verapamil.7 Following
these suggestions, the kinetics of [18F]MC225 were also
evaluated using 30 min of scan data. The same results were
obtained for 30 and 60 min scans. The kinetic parameters such
as VT, K1, and k2 were calculated using 1TCM which was
selected as the preferred model. No significant changes in the
K1 were observed, and the same significant decrease in the VT
and increase in k2 were found in data of short scans.
All these results combined could suggest that isoflurane
anesthesia induces or activates the P-gp function at the BBB.
However, the absence of significant changes in K1 refutes this
hypothesis. Moreover, post-mortem analysis of brain tissue
with WB did not indicate any significant change in P-gp or
BCRP expression in animals pre-exposed to anesthesia. Thus,
isoflurane anesthesia does not increase the expression of P-gp
at the BBB.
Taken together, our results confirm that K1 is indeed the
best parameter to measure P-gp function at the BBB, since the
lack of significant changes in K1 in animals exposed to
anesthesia corresponds to the absence of significant changes in
P-gp expression shown by WB. Moreover, this study suggests
that values of VT and k2 should be used with caution, since
these values may change in longitudinal studies for unknown
reasons.
The observed changes in VT are in accordance with recent
studies indicating that anesthesia may cause changes in the
distribution or binding affinity of PET tracers.20 For example,
the use of chloral hydrate and ketamine markedly increases,
and pentobarbital decreases, the binding potential of [11C]-
SCH23390 to dopamine D1 receptors compared to that in
conscious rats.12 Ketamine/xylazine also increases the binding
potential of [11C]MNPA to D2 receptors compared to the
binding in conscious animals.21 Chronic diazepam treatment
reduces the global uptake of [18F]FDG in the rat brain.22
Moreover, isoflurane anesthesia seems to affect the sensitivity
of agonist tracers for dopamine D2 receptors in an amphet-
amine challenge,23 and to alter the metabolism of the P-gp
tracer [11C]-N-desmethyl-loperamide.3 Furthermore, a pro-
longed effect of sevoflurane has been observed on the kinetics
of [11C]raclopride in nonhuman primates.24
These changes can also be explained by changes in CBF.20
General anesthetics are known to affect CBF, e.g., propofol
causing a decrease, whereas ketamine, isoflurane, sevoflurane
and halothane cause a slight increase or do not affect global
CBF.20,25−27 Since isoflurane is expected to increase CBF,28,29
the brain uptake of [18F]MC225 should have increased in
animals pre-exposed to anesthesia. However, we did not
observe any increase but rather a significant decrease in VT.
Moreover, whole-brain SUV of the tracer in the initial frames
and the K1 values were not significantly different in the three
study groups, suggesting that CBF was not significantly
affected by previous exposure to anesthesia.
VT values at “Test” and “Retest” were significantly different
in most of the regions analyzed, whereas K1 values were not.
The K1 values showed an overall TRV% lower than 10%;
however, in the case of VT, TRV% was around 20%. ICC values
indicated a moderate agreement between Test- Retest K1
values and only slight agreement for the VT values. These
results suggest that K1 values show better reproducibility and
reliability than VT. Therefore, in longitudinal studies aimed to
assess the P-gp function under different conditions, K1 should
be used.
The present study found a significant increase in k2 values
which led to a significant decrease of VT values of [
18F]MC225
inside the brain of animals pre-exposed to anesthesia.
However, the study did not find significant changes in the
K1, which is considered as the best parameter to measure the
P-gp function. These results were supported by the WB
experiment which did not find any significant increase in the P-
gp or BCRP expression of animals pre-exposed to anesthesia.
Overall, our results suggest that isoflurane-anesthesia affects
the brain distribution of [18F]MC225 causing changes in VT
and k2; however, anesthesia does not alter P-gp expression at
the BBB. Longitudinal studies with [18F]MC225 are possible if
K1 is used to estimate the function of P-gp.
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3. METHODS
3.1. Chemicals. The precursor of [18F]MC225, 5-[3-(6,7-
dimethoxy-3,4-dihydro-1H-isoquinolin-2yl)-propyl]-5,6,7,8-tetrahy-
dro-naphthalen-1-ol (MC226), was purchased from Syncom
(Groningen, The Netherlands). Chemicals were purchased from
Sigma-Aldrich (St.Louis, MO), and isoflurane was purchased from
Pharmachemie (Haarlem, The Netherlands).
3.2. Tracer Production. [18F]MC225 was synthesized as
previously described.9
3.3. Animals. Thirteen healthy male Wistar rats were purchased
from Janvier Laboratories (France). Before the start of the
experiments, rats were acclimatized for at least 7 days. Rats were
housed individually after the first procedure. The room was kept at a
constant temperature (21 ± 2 °C) with a 12/12 h light/dark regimen.
The rats were fed ad libitum, and water was always available. Rat
weight (354 ± 38 g) and behavior were monitored throughout the
entire study. All applicable institutional and/or national guidelines for
the care and use of animals were followed. The experiments were
performed in compliance with Dutch and EU regulations. The
protocol was approved by the National Committee on Animal
Experiments of The Netherlands (CCD, the Hague) and the
Institutional Animal Care and Use Committee of the University of
Groningen (CCD license number: AVD105002015166, IvD protocol
15166-01-002).
Moreover, 17 Wistar rats (Janvier Laboratories, France) were used
for WB studies. Rats were acclimatized for at least 7 days and were
housed in groups (3 rats per cage). The rats were kept under
controlled environment conditions (constant temperature of 22 ± 1
°C and 12 h light/12 h dark cycle and 60 ± 5% humidity). Food and
water were allowed ad libitum. The weight (354 ± 26 g), and the
behavior of the rats was monitored during the study. The
experimental protocol was approved by the local Animal Care
Committee according to the European Union (EU) rules (86/609/
CEE, 2003/65/CE, and 2010/63/EU).
3.4. Study Design. Regarding the PET studies, rats were divided
into two groups. Group 1 was used to evaluate the effect of the
anesthesia on the P-gp transporters and group 2 was used to assess the
reproducibility of [18F]MC225 data, with an interval of 1 week
between the scans. On day 7, after arrival and acclimatization, group 1
animals (n = 7) were transported to the PET facility and anesthetized
with isoflurane in oxygen (5% for induction, 1.5−2% for maintenance,
during 72 ± 17 min), whereas group 2 animals (n = 6) were
transported but not subjected to anesthesia. On day 14, a dynamic
PET scan with arterial blood sampling (60 min) was made for all rats.
The scan of group 1 (made after previous exposure to anesthesia) was
referred to as “Anesthesia-exposed”, and the first scan of group 2 was
indicated as “Test” (these animals had not been previously exposed to
anesthesia). On day 21, a second dynamic PET scan was made for the
rats of group 2. This scan is referred to as “Retest” (study design
details in Figure 8). All PET scans were performed under isoflurane
anesthesia. Thus, “Retest” animals had been previously exposed to
anesthesia, during their “Test” scan. Therefore, in “Anesthesia-
exposed” and “Retest” PETs, the animals were anesthetized twice, and
in the “Test” animals were anesthetized only once. Before each scan, a
cannula was placed in a side branch of the femoral artery for blood
sampling during the scan.30 During this surgery, the rats were also
under anesthesia for about 30 min. Anesthesia for surgery and PET
scanning lasted 86−120 min. It is important to note that, at the
“Retest” scan, animals of group 2 had also been subjected twice to
surgery (cannula placement), which may have induced extra stress.
The body temperature of anesthetized animals was maintained close
to the normal value with heating pads and electronic temperature
controllers. Blood oxygenation and heart rate were continuously
monitored during the scan, using pulse oximeters.
Rats from WB studies were divided into three groups (Figure 9).
The “Test” group (n = 6) was exposed to isoflurane anesthesia only
once, on day 14. The “Retest” group (n = 6) was exposed twice to
anesthesia, on days 7 and 14; and the control group (n = 5) was not
previously exposed to anesthesia. The anesthesia exposure consisted
of 6 ± 1 min for induction (4%, 2.1 L/min) and 89 ± 5 min for
maintenance (2%, 1.5 L/min). During maintenance, rats were
anesthetized with a mask and the body temperature was controlled
and kept close to normal values with a heating pad. On day 14, all rats
were terminated by decapitation under deep anesthesia after
phosphate buffered saline (PBS) perfusion and brains were
immediately collected. The brain tissue was flash-frozen in liquid
nitrogen and stored at −80 °C until samples were analyzed.
3.5. PET Data Collection. Anesthetized rats were placed in the
PET camera (Focus 220; Siemens Medical Solution Inc.). The head
of the rats was placed in the field of view.
First, a transmission scan was made using a 57Co point source for
attenuation and scatter correction. Rats were then injected with
[18F]MC225 via a tail vein (32.5 ± 5.5 MBq, in 1 mL during 1 min,
using a Harvard infusion pump), and the dynamic emission scan of 60
min was started simultaneously.
PET images were normalized and corrected for attenuation and
decay. Emission sinograms were iteratively reconstructed using
OSEM 2D, 4 iterations, and 16 subsets. The list-mode date of the
emission scan was reconstructed into 21 frames (6 × 10; 4 × 30; 2 ×
60; 1 × 120; 1 × 180; 4 × 300; 3 × 600 s).
3.6. Blood Data Collection. During the scan, blood samples
(0.1−0.15 mL) were drawn from the arterial cannula at 10, 20, 30, 40,
50, and 60 s and 1, 1.5, 2, 3, 5, 7.5, 10, 15, 30, and 60 min after tracer
injection. The total volume drawn was less than 2 mL. A 25 μL
sample of whole-blood was used for radioactivity measurements. The
remaining volume of the samples was centrifuged at 6000 rpm (Mikro
20, Hettich, Germany) for 5 min to separate blood and plasma. A
volume of 25 μL of plasma was taken for radioactivity measurements
and placed on ice to limit tracer metabolism. The radioactivity in
blood and plasma was measured with a γ-counter (LKB Wallac,
Turku, Finland), and values were corrected for decay.
The fractions of the parent [18F]MC225 and of radioactive
metabolites were determined using thin-layer chromatography (TLC)
analysis. Plasma proteins were precipitated by the addition of
acetonitrile (50 μL) to the plasma samples. After measurement of
radioactivity in the γ-counter, plasma samples were mixed by
vortexing for less than 1 min and were centrifuged for 5 min at
6000 rpm (Hettich Mikro 20, Hettich Zentrifugen, Germany) to
obtain a protein-free supernatant. A 2.5 μL sample of each
supernatant was spotted on a silica gel TLC plate. The TLC plate
was eluted with 10% MeOH in EtOAc and was placed on an activated
phosphor storage plate overnight. The storage plates were read using
a Cyclone system (PerkinElmer Life and Analytical Science, Waltham,
MA). OptiQuant 03.00 software (PerkinElmer) was used to calculate
the fractions of parent tracer (Rf = 0.8−0.9) and radioactive
metabolites (Rf = 0.2).
3.7. Input Function Analysis. Measured radioactivity in blood
samples was corrected for decay from the time of tracer
administration. The time−activity curves (TAC) of whole-blood,
plasma, and metabolite-corrected plasma were expressed as stand-
ardized uptake value (SUV): SUV = radioactive concentration (MBq/
ml)/[injected dose (MBq)/body weight (g)]. The metabolite-
corrected plasma TAC-SUV was obtained by multiplying the SUV
values of the plasma samples by the parent fraction.Figure 8. PET study design: group 1 (above) and group 2 (below).
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A single exponential curve was fitted to the TAC-SUV of
metabolite-corrected plasma (using values from 62 to 3564 s) by
iterative nonlinear least-squares approach using GraphPad software
(GraphPad Prism version 7.02, San Diego, CA) to calculate the
biological half-life of the tracer (T1/2): Y = Y0 exp(−KeX), where Y is
the metabolite-corrected SUV value in plasma, Y0 is the Y-intercept,
Ke is the first-order rate constant of elimination, and X is the time.
Tracer biological half-life was calculated as T1/2 = ln(2)/Ke.
31
3.8. PET Image Processing. All PET images were automatically
registered by rigid transformation to a [18F]MC225 specific template,
which was spatially aligned to a T2-weighted MRI of a Wistar rat in
Paxinos space.32 Images were processed using PMOD v3.8 software
(PMOD Technologies, Zürich, Switzerland).
Sixteen volumes of interest (VOI) were selected from a rat brain
atlas:32 amygdala, cerebellum, corpus callosum, medial geniculate,
mesencephalic, septum, superior colliculus, striatum, cortex, hippo-
campus, hypothalamus, midbrain, brainstem, thalamus, basal ganglia,
and whole brain. The radioactivity concentration was calculated for
each selected brain region to generate TACs, and it was expressed as
SUV.
3.9. Pharmacokinetic Modeling. The TACs of whole-blood and
plasma corrected for metabolites were used for pharmacokinetic
modeling using PMOD v3.8. In this study, 1TCM and 2TCM were
evaluated using 30 and 60 min scan duration. The most appropriate
model was selected based on the Aikake Information Criterion (AIC)
which measures the goodness of the fit. The standard errors (SE%) of
the estimated parameters were also taken into account during the
model selection. The cerebral blood volume fraction was fixed to 5%
following the recommendation from a previous preclinical study.10
The most appropriate model was used to calculate the influx (K1) and
efflux (k2) rate constants and the volume of distribution (VT).
3.10. Test−Retest Analysis. The reproducibility of [18F]MC225
scans was evaluated using the Rel. Diff. % between “Test” and
“Retest” scans, TRV% between both measurements and the between-
subject standard deviation was evaluated with the CV% for “Test” and
“Retest” measurements. All these parameters were calculated
according to methods of Elmenhorst et al.33
Relative Differences (Rel. Diff%)
(Retest Test)/Test 100= [ − ] ×
Test Retest Variability (TRV%)
(Retest Test)/((Retest Test)/2) 100
−
= [ − + ] ×
Coefficient of Variance (CV%) (SD/mean) 100= ×
The reliability of the measurements between and within subject was
evaluated using the ICC. This analysis was performed using a 2-way
mixed model with absolute agreement type and a confidence interval
of 95%. IBM SPSS Statistics version 23 (Armonk, NY) was used. ICC
values between 0 and 0.2, 0.3 and 0.4, 0.5 and 0.6, 0.7 and 0.8, and 0.9
and 1 are categorized as slight, fair, moderate, substantial and almost
perfect agreement, respectively.30,34
3.11. Blood Flow Analysis. In the case of tracers with high
extraction fraction, the early frames of a dynamic PET scan provide
information about tracer delivery and, thus, about blood flow
changes.35 Since [18F]MC225 has a logD of 3, it is considered as a
lipophilic tracer with a high extraction fraction.9 Hence, in order to
assess changes in blood flow after a previous exposure of animals to
anesthesia, SUV values for whole-brain were calculated from frame 3
to 12 (from 20 to 300 s).
3.12. Western Blot Analysis. P-gp and BCRP expression were
quantified by means of WB. Protein extraction was carried out adding
cold RIPPA buffer (Sigma, USA) with protease inhibitor cocktail
(Sigma, USA) to brain slices in an approximated 10:1 proportion
(volume/weight) and tissue disruption was performed in a
TissueLyser II instrument (Qiagen, Switzerland). Then tissue lysates
were centrifuged for 30 min at 20 000g, and supernatants were
collected to perform WB. Protein concentration in the lysates was
quantified using the Micro BCA Protein assay kit (Thermofisher,
USA).
The necessary volume of cell lysate containing a total amount of 50
μg of protein was subjected to SDS-PAGE in 4−15% Criterion TGX
Precast Midi Protein Gel (BioRad, USA) using a constant voltage of
140 V. Then proteins were transferred onto a PVDF membrane
(Millipore, Ireland) using a Trans-Blot semidry system (Bio-Rad,
USA) with a limited voltage of 25 V and 180 milliamps for two hours.
After the blotting step, membranes were blocked for 1 h with a 3%
bovine serum albumin (BSA) solution (in Tris-chloride buffer with
0.1% Tween 20 (TBST)). Once blocked, target proteins were
detected through the incubation with primary antibodies against P-gp
(rabbit monoclonal to P glycoprotein ab170904, Abcam, UK), BCRP
(rabbit polyclonal to BCRP/ABCG2 ab63907, Abcam, UK), and β-
actin (mouse monoclonal to β-Actin ab8226, Abcam, UK) diluted to
1:1000, 1:1000, and 1:5000, respectively, in TBST with 3% BSA.
Primary antibodies were incubated overnight at room temperature
under agitation, and then membranes were washed three times in
TBST in order to remove the excess of primary antibodies and avoid
unspecific signaling. As secondary antibodies, HRP-conjugated goat
anti-rabbit IgG (P044801-2, Dako, Denmark) and HRP-conjugated
rabbit anti-mouse IgG (P026002-2, Dako, Denmark) were used. They
were diluted to 1:5000 in TBST with 3% BSA and incubated for 1 h at
room temperature under agitation. Eventually, after washing, the HRP
activity was revealed with Pierce ECL Western Blotting Substrate
(Thermo Fisher, USA) and detected in a Chemi Doc MP imaging
system (BioRad, USA).
WB results were analyzed measuring the mean gray value of protein
bands delimited in regions of interest using ImageJ software. The
relative expression of P-gp and BCRP to β-actin was calculated for
each sample, and the average of samples for each group was
normalized to the control.
Figure 9. Western Blot study design.
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3.13. Statistical Analysis. Results are presented as mean ± SE or
EMM ± SE unless otherwise indicated. IBM SPSS Statistics version
23 was used for statistical analysis. Group differences in VT, K1, k2,
SUV-TACs, and T1/2 were assessed by generalized estimated equation
(GEE) with the independent matrix.36 Results were considered
statistically significant at p < 0.05, without correction for multiple
comparisons. The variability of VT and the rate constant k2 between
“Test” and “Retest” (or “Test” and “Anesthesia-exposed”) was
calculated using the “Test” scan as the reference, using the formulas:
(VT(k2) “Anesthesia-exposed” − VT(k2) “Test”)/VT(k2) “Test” and
(VT(k2) “Retest” − VT(k2) “Test”)/VT(k2) “Test”. Both values are
expressed as percentages. Differences in injected dose, molar activity,
radiochemical purity, and body weight between “Test” and “Retest”
scans (Group 2) were evaluated using paired t test, and p values <0.05
were considered statistically significant.
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contract, T.S. (CPII17/00027) is a recipient of a research
contract from the Miguel Servet Program (National Institute of
Health Carlos III), and M.R.-P. is a recipient of a Xunta de
Galicia fellowship PhD program (IN606A-2018/031).
Notes
The funders had no role in the study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.
The authors declare no competing financial interest.
■ REFERENCES
(1) Gameiro, M., Silva, R., Rocha-Pereira, C., Carmo, H., Carvalho,
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